Lexeo Therapeutics, Inc.
LXEOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. With a market capitalization of $368.3M, it sits in small-cap territory. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Market Cap
$368.3M
Beta
1.43
P/E (TTM)
—
P/E (Fwd)
-3.77
EPS (TTM)
$-1.12
EPS (Fwd)
$-1.24
ROE
-54.8%
ROA
-32.5%
Cash
$193.0M
Total Debt
$7.4M
Free CF
-$67.3M
52W Change
13.0%
Annual Financials
Cash vs Debt
Lexeo Therapeutics, Inc. holds $193.0M in cash against $7.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$67.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -54.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $654K (2022) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, LXEO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LXEO.